SITADOC 50

Distributor inventory

Type 2 diabetes mellitus (to improve glycaemic control) as monotherapy or as add-on with other antidiabetic medicines along with diet and exercise

Sitagliptin is a DPP-4 inhibitor. It increases levels of incretin hormones (GLP-1, GIP), which increase insulin release and decrease glucagon secretion in a glucose-dependent manner, lowering blood sugar with a low risk of hypoglycaemia when used alone.

Tablet; take exactly as prescribed. Usually taken once daily, with or without food, at the same time each day. If used with other antidiabetics, follow the doctor’s regimen; do not stop abruptly.

Headache, nasopharyngitis/common cold, upper respiratory tract infection, nausea, diarrhoea, stomach discomfort

Not for type 1 diabetes or diabetic ketoacidosis. Use caution in kidney disease—dose adjustment may be required; monitor renal function. Rare but serious: pancreatitis (severe abdominal pain), hypersensitivity reactions (rash, swelling, breathing difficulty), severe joint pain; seek medical help if these occur. Risk of hypoglycaemia increases when combined with sulfonylureas or insulin. Inform doctor about history of pancreatitis, gallstones or high triglycerides.

Insulin and sulfonylureas (increased hypoglycaemia risk), digoxin (may increase digoxin levels—monitor), strong P-gp/CYP3A4 inhibitors/inducers may affect exposure (clinical relevance usually limited)

Store below 25°C in a cool, dry place. Protect from moisture and direct light. Keep out of reach of children.

Januvia 50 Tablet, Istavel 50 Tablet, Zita 50 Tablet, Sita 50 Tablet, Janumet (sitagliptin+metformin) (as alternative if combination needed)